Oncology Market Access in India - The Commercial Potential is High, but Many Challenges Remain

NEW YORK, Jan. 17, 2012  /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

http://www.reportlinker.com/p0760646/Oncology-Market-Access-in-India----The-commercial-potential-is-high-but-many-challenges-remain.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=General_Medicine_and_Specialty_Medicine

Introduction

The Indian oncology market is forecast to grow strongly in the next decade, driven by the rise in cancer incidence and diagnosis, improved access to cancer therapies, better health insurance coverage, and higher pharmaceutical spending, particularly among the growing middle class. But while pharmaceutical companies are keen to establish a strong presence in India, a number of challenges remain

Features and benefits

* Analysis of the current epidemiology and trends within the Indian oncology market* In-depth analysis of the opportunities and threats for oncology companies in India* Discussion of key multinational and domestic companies in the Indian cancer market* An analysis of the key factors for success in India in the context of the overall healthcare industry

Highlights

A large part of the Indian population lacks access to appropriate cancer care. A number of reasons contribute to this including inadequate healthcare infrastructure, low health insurance coverage, poor education and low cancer awareness.While domestic companies dominate the market with branded generics, all major multinational pharmaceutical companies have a presence in India, targeting a small but significant part of the population that can afford the price premium associated with global brands.As the Indian economy continues to grow, more people will gain the financial ability to seek cancer treatment, while the growing middle class will drive demand for innovative branded therapies. Plans to increase government expenditure on health and improve access to cancer drugs will also drive the uptake of cancer therapeutics in the future

Your key questions answered

* Appreciate the structure of cancer care delivery in India, as well as the factors that influence the nature and quality of cancer treatment* Evaluate the opportunities and threats facing multinational companies wishing to establish or expand their presence in the Indian oncology market* Identify strategies for market penetration and appreciate the key factors for commercial success

Scope of the analysisDatamonitor insight into the Indian oncology marketRelated reportsUpcoming reportsOVERVIEWCatalystSummaryCANCER EPIDEMIOLOGY IN INDIABackground of cancer registration in IndiaMost common cancersCancer temporal trendsCancer mortality rate trendsDRIVERS OF CANCER EPIDEMIOLOGY IN INDIAPopulation dynamicsPopulation in major urban agglomerations of IndiaRisk factors driving cancer epidemiology in IndiaDietary factorsInfectious agentsEnvironmental and occupational exposuresPhysical activity, overweight, and obesityLimitations of Indian cancer dataMARKET OVERVIEWKey findingsStructure of cancer careIndia has a layered cancer care delivery systemAccess to oncology servicesThere is a lack of certified medical oncologists in IndiaAccess to cancer care is limited for a large part of the Indian populationLow insurance coverage makes cancer care unaffordable for mostThe wealthy and middle-class seek high-quality care in the private sectorCancer treatmentGeneric therapies dominate the market in IndiaGeneric versions exist for many small molecule cancer therapiesDespite patent protection, market exclusivity is not guaranteed in the Indian oncology marketCurrent treatment is based on US and European guidelinesA number of factors compromise the delivery of high-quality, evidence-based cancer careThe drug distribution systemKEY COMPANIESKey findingsOverview of the Indian oncology marketMost global compannies operate in the Indian oncology marketMultinational corporationsRocheNovartisDomestic companiesDr. Reddy'sRecent deals and alliances of Natco in oncologyDeals and alliances in the Indian oncology marketResearch and development agreementsAgreements in the oncology diagnostics sectorGenerics manufacturing and co-marketing agreementsJoint ventures in the Indian oncology marketMARKET ACCESSKey findingsStrategies for market penetrationOverview of general market entry strategies in IndiaLaunching novel, patented products remains the most viable strategy for growth in oncologyCompanies should increase their reach in the small- and mid-sized cities and rural areasTargeting key cancer indications can help increase the potential patient baseThe use of patient assistance programs may enhance brand awarenessSWOT analysis of the Indian oncology marketStrengthsWeaknessesOpportunitiesThe government is prioritizing cancer treatment, with plans to improve access to cancer drugsIndia is an attractive market in which to perform clinical trialsThreatsPrice controls may further impact pharma's pricing powerThe use of compulsory licenses may effectively end market exclusivity for many cancer drugsGrowth of the biosimilars market will minimize commercial attractiveness for foreign developersConcern over multinational M&A activity has tightened barriers to entry for foreign pharma companiesDomestic companies may invest heavily in R&D, competing for a share of the branded marketCounterfeit drugs are a threat to patients and sales revenuesBIBLIOGRAPHYJournal papersWebsitesDatamonitor reportsOtherAPPENDIXContributing expertsReport methodology

More  

Check our  

Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker